Clinical Scientist

We are seeking an experienced clinical scientist to successfully strategize and execute a clinical development plan for engineered IgM-based pipeline molecules, starting from First in Human Phase I studies, primarily conducted in the U.S and primarily in Oncology indications.

Qualifications:

  • Advanced scientific or clinical degree (eg PhD, PharmD, MPH, MD, etc).
  • 5 or more years clinical trial experience (must demonstrate a minimum of 2 years clinical trial experience in pharma/biotech industry).
  • Data listing review experience is preferred.
  • Experience authoring experimental protocols and/or study results and conclusions.
  • Relevant therapeutic area experience.
  • In-depth understanding of Phase I (and beyond) drug development.
  • Experience in the principles and techniques of data analysis, interpretation.
  • Sound knowledge of medical aspects of GCP (Good Clinical Practice), ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), FDA, EMEA, NICE and other relevant guidelines and regulations.
  • Proven abilities to perform Clinical Scientist responsibilities with increasing expertise and independence.
  • Track record of working well with other scientists and clinicians is highly valued.
  • Must be able to commute to Mountain View.
  • Able to travel (<20%).

Responsibilities:

  • Participate in Development teams, and clinical trial teams.
  • Work with Clinical Development, Clinical Operations, Drug Safety, Biostatistics, Regulatory, and Biomarker groups.
  • Develop clinical strategies.
  • Lead clinical trial protocol development, and amendments.
  • Literature research and review in disease/program area.
  • Assist with completion and submission of regulatory filings and other regulatory documentation.
  • Work with clinical teams on study site visits, and protocol training.
  • Contribute to Investigator Meetings, and Investigator/study calls.
  • Work with Clinical Operations and Medical Directors to develop consistent language and criteria for the Informed Consent Form (ICF), protocol eligibility, protocol dose modification, protocol safety, Case Report Forms (CRFs), CRF instructions, etc.
  • Assist with Medical monitoring inquiries, and participates in safety meetings and tracks, analyzes and reports any potential safety events.
  • Work with Medical Directors, Clinical Operations, Biostatistics, and other groups to conduct clinical review of study data.
  • Review, analyze, and discuss clinical study reporting documents with Medical Directors.
  • Slide deck preparation for communicating clinical development plans, clinical trial timelines, clinical data.
  • Support Medical Directors in preparing for internal/external meetings and presentations
  • Drafting and/or reviews of abstracts, posters, and coordinates further reviews with internal partners and stakeholders.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

Senior Research Associate, Discovery Biology

We are seeking a Senior Research Associate in the Discovery Group with a background in immunological, biochemical, and protein chemistry techniques. In this important position, you should have a good understanding of human and mouse immune systems, extensive experience in various immunological assays such as recall antigen assay, mixed lymphocyte reaction assay etc. You should also have experience with small scale protein production, purification and characterization. Experience with high throughput cell-based assays and assay automation with liquid handling robots is also highly desired.

Qualifications:

  • Master’s degree in biological sciences or related field with 2 years’ experience, or Bachelor’s degree (BS) with 4 years’ experience in biotech industry.
  • Familiar with human and mouse immune systems. Hands on experience with various immunological assays such as T cell activation assays, cytokine release assays, recall antigen assay, and mixed lymphocyte reaction assay, etc. Extensive experience in multi-color flow cytometry is required.
  • Experience with mammalian cell culture and transfection, protein purification and characterization (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc.).
  • Experience with high throughput cell-based assays with imaging and flow cytometry readouts, and assay automation using liquid handling robots is highly desired.
  • Knowledge of basic computer programs routinely used in a lab such as MS Word, PowerPoint, Excel, GraphPad etc; ability to quickly learn and master new instrument software and programs.
  • Excellent organization, interpersonal, and communication skills.
  • Being a team player and respectful of others is a must.
  • Must be able to commute to Mountain View.

Responsibilities:

  • Perform small scale protein production, purification and characterization (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc.) of candidate antibodies to support multiple therapeutic IgM projects.
  • Isolate PBMCs and immune cell subsets from buffy coat or whole blood samples. Perform in vitro functional assays such as cytotoxicity assays, T cell activation assays, cytokine release assays, recall antigen assay, and mixed lymphocyte reaction assay to evaluate candidate antibodies.
  • Perform ELISA and flow cytometry assays to analyze ex vivo samples from PK/PD animal studies, including PK ELISAs, cytokine analysis, immunophenotyping, etc.
  • Perform data analysis and generate technical reports. Ensure high-quality and timely documentation in electronic lab notebooks.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

Senior Scientist, Immuno-oncology

We are looking for a Scientist/Senior Scientist with a strong background in Immuno-oncology or Immunology to join our growing and friendly team during this exciting time in our expansion. You will play an integral role in the pre-clinical development of novel immuno-oncology therapeutics. We are looking for candidates that are highly skilled, motivated and creative scientists with hands-on experience in immunology, oncology, animal models and molecular biology with the ability to lead preclinical stage programs through conducting early stage proof-of-concept in vitro and in vivo studies and work productively as part of a team.

Qualifications:

  • PhD in immunology/oncology with a minimum of 2-5 years of industry experience.
  • Experience working with in vitro and in vivo models for proof-of-concept studies.  Ability to establish mechanistic in vitro immune cell-based assays with primary human immune cells.
  • Understanding of and ability to execute in vivo models with ability to select relevant models for mechanistic and efficacy studies.
  • Experience in flow cytometry and general molecular biological techniques including Western blotting, ELISAs, q-PCR etc.
  • Excellent interpersonal and collaborative skills, and the ability to work independently and effectively in a highly dynamic environment.
  • Experience training and supervising direct reports.
  • Proficient with basic computer programs routinely used in a lab such as MS Word, Excel, and PowerPoint, GraphPad Prism, and FlowJo.
  • Highly organized with reliable time-keeping skills and able to maintain a detailed and well-organized notebook.
  • Must have strong interpersonal and communication skills.
  • Being a team player and respectful of others is a must.
  • Able to thrive in a fast-paced, start-up environment.
  • Able to commute to Mountain View.

Responsibilities:

  • Lead research efforts to generate proof-of-concept in vitro and in vivo data for new early stage immuno-oncology programs.
  • Work closely with collaborators and CROs during the preclinical discovery and development stages.
  • Accountable for project strategy, delivery, communication and follow-up.
  • Presentation of results at internal and external meetings.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

Apply to this position

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, today announced the closing of its $102 million Series C financing. New investors included Redmile Group, Janus Henderson Investors, Vivo Capital and another large U.S.-based, healthcare-focused fund. Haldor Topsøe Holding A/S, which has funded IGM since 2010, also participated in the round.

“We are very pleased to have the support of these sophisticated healthcare-focused investors,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We look forward to working with them to realize the potential of our IgM platform to deliver new therapeutic treatments to patients with cancer.”

Proceeds from this financing will be used to advance the Company’s IgM platform technology and its proprietary oncology pipeline, including its lead program, a CD20 x CD3 bispecific antibody, which is expected to enter the clinic later this year.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that is focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies, and IGM believes it has the most advanced research and development program focused on engineered IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent advantages may provide superior performance, as compared to IgG antibodies. For more information about IGM Biosciences, its technologies and its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

Biomarker Scientist

IGM Biosciences is seeking an experienced Biomarker Scientist to successfully strategize, build and execute on the Development Biomarker efforts for our clinical programs.

Qualifications:

  • PhD or MD PhD.
  • Experience leading and executing on clinical cancer immunotherapy biomarker programs.
  • Strong drive to succeed.
  • Able to think strategically and work effectively in a fast-paced environment.
  • Excellent written and verbal communication.
  • Strong collaboration skills.
  • Able to thrive in a fast-paced, start-up environment.

 
IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of M. Kathleen Behrens, Ph.D., to its Board of Directors. Dr. Behrens has been a pioneer in the biotech industry throughout her career, beginning as an equity research analyst at Robertson Stephens & Co. She has been an industry leader in a wide variety of roles, including equity research analyst, venture capital investor, public equity investor, entrepreneur, executive, director and public policy and industry trade group committee member.

Dr. Behrens currently serves as the Chair of the Board of Directors of Sarepta Therapeutics, Inc. and has been a member of its Board since 2009.

“Kathy brings a unique perspective to IGM’s Board – one that has been shaped by a successful career as an entrepreneur, company founder, private and public investor, director, public policy expert and management advisor across the life sciences industry. IGM is honored to have her join us at this exciting point in our development,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Importantly, Kathy has first-hand experience guiding an antibody platform company from its inception as a privately held entity to a successful publicly traded company with a deep pipeline. Kathy’s financial industry experience also adds a key perspective to our Board as we look to build our infrastructure and strategy for 2019 and beyond. We are very pleased that Kathy will be joining the Company, and IGM will benefit greatly from her counsel and experience.”

“IGM is looking to unlock the inherent advantages that IgM antibodies may have over currently available IgG antibody treatments. It is the ingenuity and passion of companies like IGM that has excited and engaged me in this industry for the past 35 years, and it is why I remain a steadfast believer in its ability to evolve, innovate and create new products for the treatment of life-threatening human diseases,” commented Dr. Behrens. “I look forward to working with IGM, and I am very excited by the prospect of witnessing its progress firsthand.”

Dr. Behrens played an important role in the founding of one of the seminal antibody platform companies, Protein Design Labs, Inc. She also served as a director of the groundbreaking antibody platform company, Abgenix, Inc., from the company’s early rounds of private financings through its sale to Amgen Inc. Dr. Behrens also served as a director of Amylin Pharmaceuticals, Inc. from 2009 until its sale to Bristol-Myers Squibb Company.

Dr. Behrens serves as a member of the Steering Committee of the Coalition for 21st Century Medicine, of which she was a co-founder. She has served as a member of the President’s Council of Advisors on Science and Technology (“PCAST”) and as chairwoman of PCAST’s subcommittee on Personalized Medicine. She has been a director on the Board on Science, Technology and Economic Policy of the National Research Council and has also served as a director, president and chairwoman of the National Venture Capital Association.

Dr. Behrens began her career in the financial services industry as an equity research analyst with Robertson Stephens & Co., where she became a general partner, managing director and venture capital investor. Dr. Behrens continued in her venture capital management capacity as a general partner for selected venture funds of RS Investments after a management-led buyout of the firm from Bank of America Corporation.

Dr. Behrens holds a Ph.D. in Microbiology from the University of California, Davis.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience 

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Misbah Tahir to the newly created position of Chief Financial Officer. Mr. Tahir joins IGM with more than twenty years of experience in finance and strategic planning, including public market financings and product launches. Most recently, Mr. Tahir was Vice President, Head of Finance at Dermira, Inc., where he helped build the finance, treasury, accounting and SEC compliance and reporting functions during a period of rapid growth, and played an integral role in the company’s initial public offering and follow-on public financings.

“We are very pleased that Misbah has decided to join the IGM team, and his skills and leadership will be pivotal to the development of our financial infrastructure, capabilities and strategy at this exciting time in our growth as a company,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “His experience in building finance and accounting organizations, managing financial and strategic planning processes and interfacing with the biotechnology capital markets will be critical to IGM as we move a potentially transformative new therapeutic approach toward clinical proof of concept studies and eventual market launch.”

“IGM is pioneering an entirely new class of therapeutic drugs for the treatment of cancer and other serious diseases through its proprietary IgM antibody technology,” added Mr. Tahir. “The potential of this platform and the inspired, passionate and determined environment that defines IGM drew me to this opportunity. I am excited to become part of this experienced team that is devoted to delivering important advances in antibody-based therapies and the treatment of urgent unmet medical needs.”

During his career in the biotechnology industry, Mr. Tahir has helped finance, advance and launch multiple new therapeutic drugs. While at Dermira, Mr. Tahir was a key member of the financing team, which raised over $750 millionto advance the company’s clinical programs and corporate development, and he was a leader in Dermira’s transition to a commercial-stage company.

Prior to his role at Dermira, Mr. Tahir was Director, Head of Commercial Financial Planning and Analysis at Onyx Pharmaceuticals, Inc., where he served as finance business partner to the Chief Commercial Officer during the U.S. and international launches of Kyprolis® for multiple myeloma and was responsible for the financial planning processes across Onyx’s product portfolio supporting annual product sales in excess of $1 billion. Before that, he was Associate Director of Revenue at Human Genome Sciences, Inc. (HGS), where he led all revenue and collaboration accounting activities during the U.S. launch of Benlysta® and was Chair of the HGS-GlaxoSmithKline Joint Finance Committee.

Prior to HGS, Mr. Tahir spent six years at Amgen, Inc. in finance and accounting management roles. He began his professional career at the global management consulting firm Oliver Wyman, where he developed business development and market-entry strategies for diverse clients.

Mr. Tahir received an MBA from the University of Michigan Business School and a BA from the University of Pennsylvania.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins Chief Medical Officer, Daniel S. Chen, M.D., Ph.D., to Build IGM’s Clinical Development Function

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Wayne Godfrey, M.D. to the newly created position of Vice President, Clinical Development.

Dr. Godfrey will help lead global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 25 years of experience in cancer immunology and immunotherapy research and development, most recently with Kite/Gilead, where he led the CAR-T CD19-directed pivotal Phase II study, ZUMA-5.

“Wayne has been a pioneer in the field of immuno-oncology, including leading the team that first identified human OX40 and OX40-Ligand with Dr. Edgar G. Engleman at Stanford, and he played an important role in the identification, culture, and characterization of human T regulatory cells at the University of Minnesota, in collaboration with Dr. Bruce R. Blazar. Wayne was an inventor on some of the seminal patents licensed in these fields, and I am honored to have the opportunity to work directly with him,” said Daniel S. Chen, Chief Medical Officer of IGM Biosciences. Dr. Chen continued, “Wayne’s scientific immuno-oncology and clinical hematology experience, combined with his proven leadership abilities as past Chief Medical Officer at Bavarian-Nordic Immunotherapeutics and Etubics, provides IGM with valuable new expertise and know-how as we build IGM’s clinical development capabilities.”

“Wayne’s experience with CAR-T approaches to lymphoma and diverse approaches to cancer immunotherapy in solid tumors will provide strong support for the development of our industry-leading IgM technology platform,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

Dr. Godfrey commented: “I’m fascinated by IGM’s innovative and proprietary engineering approach to bispecific antibodies, which offers many new avenues for creating the next generation of therapeutics for immuno-oncology and beyond. The ability to target cancer antigens that elude IgG-based therapeutics and the framework for adding multiple additional binding domains and payloads are very compelling. Importantly, the ability of multivalent IgM antibodies to powerfully stimulate signaling receptors may also enable us to realize the true potential of OX40 and other TNFr family members as immuno-oncology targets. I’m very excited to have the opportunity to study and develop the potential of IGM’s technology in the clinic.”

Dr. Godfrey conducted research and studied clinical immunology at Stanford, and then went on to run his own lab as a faculty member in Hematology, Oncology and Transplantation at the University of Minnesota and developed and patented methods to purify and culture T regulatory cells. His biotech and pharma experience has included work on antigen presenting cell vaccines, TLR agonists, and viral-prime boost vaccines in both research and global clinical development roles. Subsequently, he also served as the medical lead for multiple clinical studies of Idelalisib in lymphoma (Phase 1-4) and contributed to the filing and FDA approval of Zydelig® at Gilead Sciences. After working on CEA and HER2 targeted adenoviral cancer vaccines at Etubics/Nantcell, he most recently was the clinical development lead for anti-CD19 directed CAR-T cell studies in follicular lymphoma at Kite/Gilead.

Dr. Godfrey has co-authored multiple clinical and scientific publications, including “Identification of a human OX40 ligand, a costimulatory of CD4+ T cells with homology to tumor necrosis factor,” and “PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma,” published in The New England Journal of Medicine. He is also an inventor or co-inventor on multiple patents, including “Regulatory T cells (CD4+CD25+) and their use in immunotherapy.” Dr. Godfrey earned an M.D. from Washington University and completed his internal medicine residency and Clinical Immunology, Hematology and Bone Marrow Transplantation Fellowships at Stanford University.

Dr. Chen and Dr. Godfrey will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. Dr. Chen joined IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts